Karyopharm Therapeutics (KPTI) Stock Analysis & Winston Score

Karyopharm Therapeutics is a small biotech company that makes cancer drugs. Its main product is selinexor, sold under the brand name Xpovio, which is approved to treat certain types of blood cancers, including multiple myeloma and a cancer called diffuse large B-cell lymphoma. Karyopharm sells primarily to hospitals, cancer treatment centers, and oncology specialists in the United States. The company earns money through drug sales and licensing deals with partners in other countries. Its 96% gross margin reflects the high pricing typical of specialty cancer drugs, but it still loses money overall because of heavy spending on research and clinical trials. Karyopharm's competitive position depends on selinexor's unique mechanism — it blocks a protein called XPO1 — but the company faces serious risk from a small approved patient population, competition from established cancer therapies, and the ongoing need to fund expensive trials to expand selinexor into additional cancer types.